Please enable JavaScript to continue using this application.

Compare $CCCC vs $KYTX | Chartloom

Compare

$CCCC vs $KYTX

C4 Therapeutics, Inc · Kyverna Therapeutics Inc

CCCC

C4 Therapeutics, Inc

KYTX

Kyverna Therapeutics Inc

Compare $CCCC vs $KYTX

Comparing C4 Therapeutics, Inc and Kyverna Therapeutics Inc

CCCCC4 Therapeutics, Inc

KYTXKyverna Therapeutics Inc

CCCCC4 Therapeutics, Inc

Market cap

$349M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.01x

Rev growth (TTM)

2.3%

YTD performance

63.7%

52W performance

41.7%

FCF yield

-24.4%

KYTXKyverna Therapeutics Inc

Market cap

$389M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-27.1%

52W performance

-11.0%

FCF yield

-41.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CCCC

KYTX

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

KYTX

Kyverna Therapeutics Inc

Market Cap

CCCC$349M

KYTX$389M

Enterprise Value

CCCC$271M

KYTX$382M

Price

CCCC$3.16

KYTX$6.39

P/E Ratio

CCCCN/A

KYTXN/A

P/S Ratio

CCCC9.97x

KYTX0.00x

EV/Sales

CCCC7.73x

KYTX0.00x

EV/EBITDA

CCCC0.00x

KYTX0.00x

P/B Ratio

CCCC1.47x

KYTX2.32x

P/FCF Ratio

CCCCN/A

KYTXN/A

EV/FCF

CCCC-3.17x

KYTX-2.38x

PEG Ratio

CCCCN/A

KYTXN/A

Forward P/E (NTM)

CCCCN/A

KYTXN/A

Forward P/S (NTM)

CCCC15.01x

KYTXN/A

Revenue (TTM)

CCCC$35M

KYTX$0

Revenue Growth (YoY)

CCCC2.3%

KYTXN/A

Forward Rev Growth

CCCC-15.9%

KYTX252.6%

Gross Margin (TTM)

CCCC0.0%

KYTX0.0%

Operating Margin (TTM)

CCCC0.0%

KYTX0.0%

EBITDA Margin (TTM)

CCCC-283.8%

KYTX0.0%

Net Margin (TTM)

CCCC-289.4%

KYTX0.0%

FCF Margin (TTM)

CCCC-243.7%

KYTXN/A

Net Income (TTM)

CCCC$-101M

KYTX$-153M

FCF (TTM)

CCCC$-85M

KYTX$-160M

EPS (TTM)

CCCC-$0.78

KYTX-$2.51

ROE (TTM)

CCCC-4545.0%

KYTX-8191.0%

ROA (TTM)

CCCC-3090.0%

KYTX-6374.0%

ROIC (TTM)

CCCC-4545.0%

KYTX-7440.0%

Cash

CCCC$79M

KYTX$32M

Debt

CCCC$0

KYTX$25M

Net Cash/Debt

CCCC$79M

KYTX$7M

Current Ratio (TTM)

CCCC5.45x

KYTX9.06x

Quick Ratio (TTM)

CCCC5.29x

KYTX8.75x

Debt/Equity (TTM)

CCCC0.00x

KYTX0.15x

Debt/Assets (TTM)

CCCC0.0%

KYTX0.0%

Interest Coverage (TTM)

CCCCN/A

KYTXN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

KYTX0.00x

Beta

CCCC3.16

KYTX2.11

52W Performance

CCCC41.7%

KYTX-11.0%

YTD Performance

CCCC63.7%

KYTX-27.1%

% from 52W High

CCCC-38.9%

KYTX-53.3%

% from 52W Low

CCCC87.0%

KYTX7.2%

Asset Turnover (TTM)

CCCC0.11x

KYTX0.00x

FCF Yield (TTM)

CCCC-24.4%

KYTX-41.2%

Earnings Yield (TTM)

CCCC-29.0%

KYTX-39.3%

Dividend Yield (TTM)

CCCCN/A

KYTXN/A

Rule of 40

CCCC-241.4

KYTX0.0

EV/GP/RG

CCCCN/A

KYTXN/A

Ticker research

View CCCC research View KYTX research

Metric	CCCC C4 Therapeutics, Inc	KYTX Kyverna Therapeutics Inc
Market & Valuation
Market Cap	$349M	$389M
Enterprise Value	$271M	$382M
Price	$3.16	$6.39
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	2.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-2.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	252.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-153M
FCF (TTM)	$-85M	$-160M
EPS (TTM)	-$0.78	-$2.51
ROE (TTM)	-4545.0%	-8191.0%
ROA (TTM)	-3090.0%	-6374.0%
ROIC (TTM)	-4545.0%	-7440.0%
Financial Health
Cash	$79M	$32M
Debt	$0	$25M
Net Cash/Debt	$79M	$7M
Current Ratio (TTM)	5.45x	9.06x
Quick Ratio (TTM)	5.29x	8.75x
Debt/Equity (TTM)	0.00x	0.15x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	2.11
52W Performance	41.7%	-11.0%
YTD Performance	63.7%	-27.1%
% from 52W High	-38.9%	-53.3%
% from 52W Low	87.0%	7.2%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-41.2%
Earnings Yield (TTM)	-29.0%	-39.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View KYTX research

Valuation

P/S Ratio

KYTX

0.00x

CCCC

9.97x

EV/FCF

CCCC

-3.17x

KYTX

-2.38x

Growth & revenue

Revenue Growth TTM

CCCC

2.3%

Forward Revenue Growth

KYTX

252.6%

CCCC

-15.9%

Profitability & performance

Gross Margin

CCCC

0.0%

KYTX

0.0%

ROE

CCCC

-4545.0%

KYTX

-8191.0%

FCF Yield %

CCCC

-24.4%

KYTX

-41.2%

52-Week Performance

CCCC

41.7%

KYTX

-11.0%

Detailed metrics comparison

CCCC

C4 Therapeutics, Inc

KYTX

Kyverna Therapeutics Inc

Market Cap

CCCC$349M

KYTX$389M

Enterprise Value

CCCC$271M

KYTX$382M

Price

CCCC$3.16

KYTX$6.39

P/E Ratio

CCCCN/A

KYTXN/A

P/S Ratio

CCCC9.97x

KYTX0.00x

EV/Sales

CCCC7.73x

KYTX0.00x

EV/EBITDA

CCCC0.00x

KYTX0.00x

P/B Ratio

CCCC1.47x

KYTX2.32x

P/FCF Ratio

CCCCN/A

KYTXN/A

EV/FCF

CCCC-3.17x

KYTX-2.38x

PEG Ratio

CCCCN/A

KYTXN/A

Forward P/E (NTM)

CCCCN/A

KYTXN/A

Forward P/S (NTM)

CCCC15.01x

KYTXN/A

Revenue (TTM)

CCCC$35M

KYTX$0

Revenue Growth (YoY)

CCCC2.3%

KYTXN/A

Forward Rev Growth

CCCC-15.9%

KYTX252.6%

Gross Margin (TTM)

CCCC0.0%

KYTX0.0%

Operating Margin (TTM)

CCCC0.0%

KYTX0.0%

EBITDA Margin (TTM)

CCCC-283.8%

KYTX0.0%

Net Margin (TTM)

CCCC-289.4%

KYTX0.0%

FCF Margin (TTM)

CCCC-243.7%

KYTXN/A

Net Income (TTM)

CCCC$-101M

KYTX$-153M

FCF (TTM)

CCCC$-85M

KYTX$-160M

EPS (TTM)

CCCC-$0.78

KYTX-$2.51

ROE (TTM)

CCCC-4545.0%

KYTX-8191.0%

ROA (TTM)

CCCC-3090.0%

KYTX-6374.0%

ROIC (TTM)

CCCC-4545.0%

KYTX-7440.0%

Cash

CCCC$79M

KYTX$32M

Debt

CCCC$0

KYTX$25M

Net Cash/Debt

CCCC$79M

KYTX$7M

Current Ratio (TTM)

CCCC5.45x

KYTX9.06x

Quick Ratio (TTM)

CCCC5.29x

KYTX8.75x

Debt/Equity (TTM)

CCCC0.00x

KYTX0.15x

Debt/Assets (TTM)

CCCC0.0%

KYTX0.0%

Interest Coverage (TTM)

CCCCN/A

KYTXN/A

Net Debt/EBITDA (TTM)

CCCC0.00x

KYTX0.00x

Beta

CCCC3.16

KYTX2.11

52W Performance

CCCC41.7%

KYTX-11.0%

YTD Performance

CCCC63.7%

KYTX-27.1%

% from 52W High

CCCC-38.9%

KYTX-53.3%

% from 52W Low

CCCC87.0%

KYTX7.2%

Asset Turnover (TTM)

CCCC0.11x

KYTX0.00x

FCF Yield (TTM)

CCCC-24.4%

KYTX-41.2%

Earnings Yield (TTM)

CCCC-29.0%

KYTX-39.3%

Dividend Yield (TTM)

CCCCN/A

KYTXN/A

Rule of 40

CCCC-241.4

KYTX0.0

EV/GP/RG

CCCCN/A

KYTXN/A

Ticker research

View CCCC research View KYTX research

Metric	CCCC C4 Therapeutics, Inc	KYTX Kyverna Therapeutics Inc
Market & Valuation
Market Cap	$349M	$389M
Enterprise Value	$271M	$382M
Price	$3.16	$6.39
P/E Ratio	N/A	N/A
P/S Ratio	9.97x	0.00x
EV/Sales	7.73x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.47x	2.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.17x	-2.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	15.01x	N/A
Revenue & Growth
Revenue (TTM)	$35M	$0
Revenue Growth (YoY)	2.3%	N/A
Forward Rev Growth	-15.9%	252.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-283.8%	0.0%
Net Margin (TTM)	-289.4%	0.0%
FCF Margin (TTM)	-243.7%	N/A
Net Income (TTM)	$-101M	$-153M
FCF (TTM)	$-85M	$-160M
EPS (TTM)	-$0.78	-$2.51
ROE (TTM)	-4545.0%	-8191.0%
ROA (TTM)	-3090.0%	-6374.0%
ROIC (TTM)	-4545.0%	-7440.0%
Financial Health
Cash	$79M	$32M
Debt	$0	$25M
Net Cash/Debt	$79M	$7M
Current Ratio (TTM)	5.45x	9.06x
Quick Ratio (TTM)	5.29x	8.75x
Debt/Equity (TTM)	0.00x	0.15x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.16	2.11
52W Performance	41.7%	-11.0%
YTD Performance	63.7%	-27.1%
% from 52W High	-38.9%	-53.3%
% from 52W Low	87.0%	7.2%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.00x
FCF Yield (TTM)	-24.4%	-41.2%
Earnings Yield (TTM)	-29.0%	-39.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-241.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CCCC research	View KYTX research